Related Experiment Videos
Optimum dosing of ipilimumab in melanoma: too little, too late?
Alexander M Menzies1, Georgina V Long1
1Melanoma Institute Australia, Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia.
The Lancet. Oncology
|April 1, 2017
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Impact of adjuvant therapy on melanoma-specific survival in elderly patients with high-risk resected melanoma: a multicenter international retrospective study.
Journal for immunotherapy of cancer·2026
Anti-PD-1 Therapy and Long-Term Toxic Effects Among Patients With Melanoma.
JAMA network open·2026
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.
European journal of cancer (Oxford, England : 1990)·2026
Distinctive features of the tumor and immune microenvironment in glioblastoma.
NPJ precision oncology·2026
Cancer and the microbiome: from association to intervention.
The Lancet. Oncology·2026
RNA-seq-based transcriptome analysis identifies TCR-expressing B1 cells as a multipotent lymphoid intermediate.
Biochemical and biophysical research communications·2026
The Trolley Problem of Perioperative Immunotherapy in Head and Neck Cancer.
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale·2026